English
  • Ruxolitinib

    Ruxolitinib

    Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA)
    Ruxolitinib Myelofibrosis Novartis Oṣu Keje 6, Ọdun 2024
    ibeereapejuwe awọn
  • Relugolix

    Relugolix

    Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA)
    Relugolix Akàn pirositeti Takeda ati ASKA Oṣu Kẹta Ọjọ 24, Ọdun 2024
    ibeereapejuwe awọn
  • Rimegepant

    Rimegepant

    Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA)
    Rimegepant Orififo orififo Biohaven Oṣu kejila ọjọ 22, Ọdun 2031

     

    ibeereapejuwe awọn
  • Relugolix 737789-87-6

    Relugolix 737789-87-6

    Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP
    Ribociclib CAS: 737789-87-6 Antineoplastic Ninu Ile      
    ibeereapejuwe awọn
  • Ribociclib 1374639-75-4

    Ribociclib 1374639-75-4

    Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA)
    Ribociclib 1374639-75-4 HR-rere, HER2-odi Andvance ormetastaticbreast Awọn aarun Novartis
    Awọn oogun oogun    		 Oṣu Kẹfa Ọjọ 27, Ọdun 2028
    ibeereapejuwe awọn
  • Rivaroxaban

    Rivaroxaban

    Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP
    Rivaroxaban Anticoagulant Ninu Ile TDP    
    ibeereapejuwe awọn
  • Rosuvastatin Calcium

    Calcium rosuvastatin

    Orukọ API Itọkasi Sipesifikesonu US DMF EU DMF CEP
    Calcium rosuvastatin Hypercholesterolemia Ninu Ile / CEP Ọdun 20705 √ CEP2015-240
    ibeereapejuwe awọn